000182558 001__ 182558
000182558 005__ 20240229145722.0
000182558 0247_ $$2doi$$a10.3390/nu14214546
000182558 0247_ $$2pmid$$apmid:36364809
000182558 0247_ $$2altmetric$$aaltmetric:137789490
000182558 037__ $$aDKFZ-2022-02739
000182558 041__ $$aEnglish
000182558 082__ $$a610
000182558 1001_ $$0P:(DE-He78)a1d1b323625dcfa155b477a646cbda52$$aKuznia, Sabine$$b0$$eFirst author$$udkfz
000182558 245__ $$aEfficacy and Safety of a Personalized Vitamin D3 Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial.
000182558 260__ $$aBasel$$bMDPI$$c2022
000182558 3367_ $$2DRIVER$$aarticle
000182558 3367_ $$2DataCite$$aOutput Types/Journal article
000182558 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668427340_28554
000182558 3367_ $$2BibTeX$$aARTICLE
000182558 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182558 3367_ $$00$$2EndNote$$aJournal Article
000182558 500__ $$a#EA:C070#LA:C070#LA:C120#
000182558 520__ $$aA personalized vitamin D3 loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D3 daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D > 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (n = 5 in verum and n = 1 in the placebo group; p = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D3 daily sustained the achieved levels.
000182558 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000182558 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182558 650_7 $$2Other$$abolus
000182558 650_7 $$2Other$$acalcium
000182558 650_7 $$2Other$$acolorectal cancer
000182558 650_7 $$2Other$$aefficacy
000182558 650_7 $$2Other$$aloading dose
000182558 650_7 $$2Other$$apersonalized medicine
000182558 650_7 $$2Other$$arandomized controlled trial
000182558 650_7 $$2Other$$asafety
000182558 650_7 $$2Other$$atreatment regimen
000182558 650_7 $$2Other$$avitamin D
000182558 7001_ $$00000-0003-1217-5134$$aCzock, David$$b1
000182558 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b2$$udkfz
000182558 7001_ $$aCaspari, Reiner$$b3
000182558 7001_ $$aFischer, Harald$$b4
000182558 7001_ $$0P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aLaetsch, Dana Clarissa$$b5
000182558 7001_ $$0P:(DE-He78)6ebb9642e577b54162be85ccb2e4941f$$aSlavic, Marija$$b6$$udkfz
000182558 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b7$$eLast author$$udkfz
000182558 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b8$$eLast author$$udkfz
000182558 773__ $$0PERI:(DE-600)2518386-2$$a10.3390/nu14214546$$gVol. 14, no. 21, p. 4546 -$$n21$$p4546$$tNutrients$$v14$$x2072-6643$$y2022
000182558 909CO $$ooai:inrepo02.dkfz.de:182558$$pVDB
000182558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1d1b323625dcfa155b477a646cbda52$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000182558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6ebb9642e577b54162be85ccb2e4941f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000182558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000182558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000182558 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000182558 9141_ $$y2022
000182558 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000182558 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000182558 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000182558 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000182558 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000182558 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000182558 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000182558 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000182558 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-08-27T10:32:17Z
000182558 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-08-27T10:32:17Z
000182558 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-08-27T10:32:17Z
000182558 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000182558 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000182558 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-09
000182558 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182558 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000182558 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182558 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000182558 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000182558 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x3
000182558 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182558 980__ $$ajournal
000182558 980__ $$aVDB
000182558 980__ $$aI:(DE-He78)C070-20160331
000182558 980__ $$aI:(DE-He78)C120-20160331
000182558 980__ $$aI:(DE-He78)HD01-20160331
000182558 980__ $$aI:(DE-He78)C060-20160331
000182558 980__ $$aUNRESTRICTED